Background/Objectives: Myocarditis is a recognized complication of COVID-19 infection, with potential long-term cardiac sequelae. While acute cardiac involvement has been frequently reported, late-stage myocardial effects remain less well characterized. Cardiac magnetic resonance (CMR) imaging, particularly T1 and T2 mapping, offers non-invasive tissue characterization for myocardial inflammation and fibrosis. This study aimed to evaluate segmental myocardial tissue changes in patients with late-stage COVID-19–related myocarditis using CMR and compare findings with patients with non-COVID-19 myocarditis and healthy controls. Methods: This retrospective, single-center study included 25 patients with clinically suspected COVID-19 myocarditis who underwent CMR between 36 and 565 days post-infection. T1 and T2 mapping values and late gadolinium enhancement (LGE) patterns were assessed and compared with 14 non-COVID-19 myocarditis patients and 19 healthy controls. Subgroup analyses were performed according to vaccination status and left ventricular ejection fraction (LVEF). Results: Patients with reduced LVEF had significantly higher T1 and T2 values in several myocardial segments. Compared to controls, the COVID-19 myocarditis group showed significantly elevated T1 values in all segments except 2 and 3. No significant difference in T2 values was observed. LGE was present in 61% of COVID-19 myocarditis patients, predominantly with a subepicardial pattern. No significant differences were observed between vaccinated and unvaccinated patients. Conclusions: Late-stage COVID-19 myocarditis is associated with persistent segmental myocardial tissue abnormalities, particularly elevated T1 values and subepicardial LGE. Segmental CMR mapping may provide additional diagnostic value in identifying residual myocardial injury in patients with ongoing cardiac symptoms after COVID-19 infection.

The Anatolian Journal of Cardiology - Peer-reviewed cardiology journal publishing original research, reviews, case reports. Impact Factor 1.5. The Anatolian Journal of Cardiology - Leading international cardiology journal with Impact Factor 1.5. Publishing original research, reviews, and case reports in cardiovascular medicine. Indexed in PubMed, Scopus, and Web of Science.

Background/Objectives: The prognostic significance of young age in breast cancer (BC) remains controversial, with varying findings across studies. This study aimed to evaluate the imaging characteristics, pathological features, and survival outcomes of BC in young patients aged ≤ 35 years by dividing them into two groups and to compare outcomes between these subgroups to determine whether very young age alone is associated with worse prognosis. Methods: This retrospective study included patients aged ≤ 35 years with malignant breast lesions who underwent image-guided interventions at a single center between January 2011 and December 2024. Patients were divided into two groups: Group 1 (≤30 years) and Group 2 (31–35 years). Demographic, imaging, and pathological data, as well as survival outcomes, were analyzed. Results: A total of 34 patients (Group 1: n = 14, Group 2: n = 20) with malignant breast lesions underwent 40 image-guided procedures. No significant differences were observed between groups in imaging features, pathological characteristics, or pTNM stage distribution. Median follow-up was 68 months. One-year overall survival (OS) was 100% in both cohorts; 5-year OS rates were 100% and 92.3%, respectively, with no statistically significant difference (p = 0.784). Median event-free survival (EFS) was 60.5 months, also without a significant difference between groups (p = 0.897). None of the clinicopathological factors assessed were significantly associated with OS in this exploratory analysis. Conclusions: In women ≤ 35 years, tumor characteristics and patient outcomes were similar between those aged ≤ 30 and 31–35 years. OS and EFS were favorable in both groups, indicating that within the ≤35-year population studied, being ≤30 years old was not associated with worse outcomes than being 31–35 years old. Although advanced stage disease was more frequently observed in the younger group, this difference was not statistically significant.

This study aimed to evaluate the outcomes of transjugular intrahepatic portosystemic shunt (TIPSS) procedures performed in a very-low-volume center over 4 years, focusing on procedural success, complication rates, and clinical effectiveness in managing portal hypertension and related complications.A retrospective analysis was conducted of those who underwent TIPSS at our institution from October 2020 to October 2024. Inclusion criteria were no prior TIPSS or liver surgery and available follow-up data. Data collected included patient demographics, portal hypertension etiology, and procedural details. Success was assessed in technical, hemodynamic, and clinical categories, with complication and readmission rates analyzed.Ten patients (six male, four female; median age 45.5 years, range 12–74) underwent TIPSS between October 2020 and October 2024. TIPSS indications included refractory ascites (40%) and variceal bleeding (60%), with all procedures elective except one emergency case for acute variceal bleeding. Technical success was achieved in 90%, with one unsuccessful shunt placement in a patient due to extensive hepatic vein and vena cava thrombosis. The mean portosystemic pressure gradient (PSG) decreased from 27 ± 3.32 to 8.56 ± 1.74 mm Hg, with hemodynamic success achieved in all patients (PSG ≤ 12 mm Hg). Clinical success was observed with no rebleeding or large-volume paracentesis required within 30 days postprocedure.TIPSS can be effectively performed in a very-low-volume center, yielding favorable outcomes with manageable complications, provided it is conducted by experienced physicians following proper protocols.

Purpose: To evaluate the safety and efficacy of intra-arterial chemotherapy as a treatment for advanced intraocular retinoblastoma and to present our single-center experience. Materials and Methods: This single-center retrospective cohort study included 13 pediatric patients (15 eyes) who underwent intra-arterial chemotherapy between January 2020 and December 2024. Patients were categorized into two groups: those receiving treatment as a first-line option (group 1) and those treated following the failure of previous therapies (group 2). Data were collected on technical success, complications, ocular preservation, and visual function. Each patient was monitored for a minimum of 12 months after treatment initiation. Results: According to the ICRB classification, most eyes (66.7%) were Groups D, followed by groups C and E. The mean age at presentation was 22.5 months. A total of 45 intra-arterial chemotherapy procedures were performed, with successful catheterization achieved in 97.8% of cases. Minor procedural complications were observed in 8.8% of sessions, with no serious systemic adverse events. Visual acuity was maintained or improved in 93.3% of treated eyes. No patients required enucleation, and no cases of metastasis or death occurred during follow-up. Conclusion: Intra-arterial chemotherapy is a technically feasible and promising globe-sparing treatment for intraocular retinoblastoma, demonstrating high technical success and a favorable safety profile in our cohort. While preliminary outcomes show preserved visual function and high ocular survival, larger studies with longer follow-up are necessary to confirm long-term efficacy and safety within a multidisciplinary framework. Graphical